In the STEP weight trials, there were no significant interactions between treatment effect and race (STEP 1 and 3: p greater than or equal to 0.07) or ethnicity, and the weight loss versus placebo was clinically meaningful across every racial subgroup
[5] Some individuals may experience these effects even at moderate doses
Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H et al (2002) Drusen proteome analysis: an approach to the etiology of age-related macular degeneration
Purpose-built for physicians Human, exendin-based GLP-1 receptor agonists similarly reduce CV, renal risk in diabetes A pooled study assessing trials of eight GLP-1 receptor agonists showed all reduce risk for a combined endpoint of major adverse cardiovascular events, regardless of structural homology to human GLP-1, as well as individual CV components
10.1001/jama.2021.23619 35